Organization
Baltimore
13 abstracts
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Northwestern Memorial Hospital, Chicago, IL, Chicago, IL, Il-Yang Pharmaceuticals, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
CSF proteomics for predicting response to treatment in patients with primary and secondary central nervous system lymphoma.Org: Penn State College of Medicine, University Park, PA, PainReform, University of Toronto, Toronto Allergy and Asthma Centre,
Abstract
Socioeconomic disparities in survival outcomes of patients with SCLC with brain metastases: A nationwide analysis.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Flare Therapeutics, St. John's Medical College, Bangalore, India, Bangalore Medical College And Research Institute,
Abstract
Validation of a digital pathology-based multimodal artificial intelligence model in oliogmetastatic castration-sensitive prostate cancer, including in patients from the STOMP and ORIOLE phase II randomized clinical trials.Org: Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD Anderson Cancer Center, New Brunswick, NJ,
Abstract
The factors associated with all-cause in-hospital mortality in patients with malignant well-differentiated gastroenteropancreatic neuroendocrine tumors: A retrospective analysis of National Inpatient Survey (NIS) 2020 dataset.Org: Internal Medicine Residency, Jefferson-Einstein Hospital, Philadelphia, PA, PainReform, Johns Hopkins University Bloomberg School of Public Health,
Abstract
Secondary primary malignancy risk by ER, PR, and HER-2 status in post-menopausal women with breast cancer: A population-based analysis.Org: King Edward Medical University, Lahore Medical Research Center, Pakistan, King Edward Medical University Pakistan, Jhelum,
Abstract
Physician-reported barriers and strategies to using tumor mutational burden (TMB) testing in oncology care: An interview based study.Org: Merck and Co., Inc, Rahway, NJ, Merck & Co., Inc., OPEN Health, Parsippany,
Abstract
AN INDIRECT COMPARISON OF THE EFFICACY OF RITUXIMAB AND ABATACEPT IN RHEUMATOID ARTHRITIS (RA) PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNF THERAPYOrg: Arthritis Center of Nebraska, Harbor Hospital, Medicine, Kuopio University Hospital, Kuopio, University of Maryland School of Medicine, Baltimore,
Abstract
ASSOCIATION OF WEIGHT CHANGE WITH CHANGES IN KNEE PAIN AND FUNCTION IN PERSONS WITH SYMPTOMATIC KNEE OSTEOARTHRITIS: DATA FROM THE OSTEOARTHRITIS INITIATIVEOrg: University of Maryland Capital Region, The Johns Hopkins University School of Medicine, Baltimore,
Abstract
BELIMUMAB (BMAB), A FULLY HUMAN MONOCLONAL ANTIBODY TO B-LYMPHOCYTE STIMULATOR (BLYS), SHOWS BIOACTIVITY AND REDUCES SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITYOrg: LBSL02 Study Grp, Cedars-Sinai Comprehensive Cancer Center, UCLA Department of Medicine, Los Angeles Medical Center, UA AHSC,
Abstract
BELIMUMAB (FULLY HUMAN MONOCLONAL ANTIBODY TO BLYS) IMPROVED OR STABILIZED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE ACTIVITY AND REDUCED FLARE RATE DURING 3 YEARS OF THERAPYOrg: NSLIJHS, Lake Success, NY, Lake Success, NY, JHU, Baltimore, Cedars-Sinai Comprehensive Cancer Center,